Literature DB >> 8302581

p53 mutations in HPV-negative cervical carcinoma.

D J Park1, S P Wilczynski, R L Paquette, C W Miller, H P Koeffler.   

Abstract

Human papillomavirus (HPV) infection has been strongly linked to the development of cervical carcinoma. Two viral oncoproteins, E6 and E7, produced by HPV, have been shown to immortalize primary human genital epithelial cells by interacting with the protein products of cellular tumor suppressor genes p53 and Rb, respectively. E6 binds to the cellular p53 protein promoting p53 degradation and inactivity. This mechanism has been suggested to contribute to the oncogenesis of HPV-positive anogenital cancers. In HPV-negative cervical carcinoma, p53 mutation is thought to be the possible mechanism of oncogenesis. We have studied 257 cervical carcinoma specimens for HPV infection by Southern blot analysis and polymerase chain reaction (PCR). Of 257 samples, 39 were HPV-negative. We have further studied 21 HPV-negative specimens for p53 mutations utilizing PCR amplification of genomic DNA followed by single-stranded conformation polymorphism (SSCP) analysis and DNA sequencing. We found only two missense point mutations of p53 gene. In summary, although inactivation of p53 mediated either by E6 or by mutations may be an important key step in the development of cervical carcinoma, our study suggests that other mechanisms may also be involved in development of cervical cancer.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8302581

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  15 in total

1.  p53 expression in carcinoma of the cervix.

Authors:  C R Hunt; R J Hale; C H Buckley; J Hunt
Journal:  J Clin Pathol       Date:  1996-12       Impact factor: 3.411

2.  The carcinogenic role of oncogenic HPV and p53 gene mutation in cervical adenocarcinomas.

Authors:  S Andersson; A-C Hellström; Zhi-Ping Ren; E Wilander
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

3.  Activation of p53 in cervical carcinoma cells by small molecules.

Authors:  S Hietanen; S Lain; E Krausz; C Blattner; D P Lane
Journal:  Proc Natl Acad Sci U S A       Date:  2000-07-18       Impact factor: 11.205

Review 4.  Human papillomaviruses and cervical neoplasia. II. Interaction of HPV with other factors.

Authors:  C S Herrington
Journal:  J Clin Pathol       Date:  1995-01       Impact factor: 3.411

5.  A Detailed Immunohistochemical Analysis of a Large Series of Cervical and Vaginal Gastric-type Adenocarcinomas.

Authors:  Claire Carleton; Lien Hoang; Shatrughan Sah; Takako Kiyokawa; Yevgeniy S Karamurzin; Karen L Talia; Kay J Park; W Glenn McCluggage
Journal:  Am J Surg Pathol       Date:  2016-05       Impact factor: 6.394

6.  Abnormal expression and mutation of p53 in cervical cancer--a study at protein, RNA and DNA levels.

Authors:  H Y Ngan; S W Tsao; S S Liu; M Stanley
Journal:  Genitourin Med       Date:  1997-02

7.  Analysis and clinical implications of p53 gene mutations and human papillomavirus type 16 and 18 infection in primary adenocarcinoma of the uterine cervix.

Authors:  P Tenti; S Pavanello; L Padovan; A Spinillo; N Vesentini; R Zappatore; P Migliora; C Zara; G N Ranzani; L Carnevali
Journal:  Am J Pathol       Date:  1998-04       Impact factor: 4.307

8.  Immunohistochemical expression of mdm2 and p21WAF1 in invasive cervical cancer: correlation with p53 protein and high risk HPV infection.

Authors:  G Troncone; J C Martinez; L Palombini; G De Rosa; C Mugica; J A Rodriguez; P Zeppa; D Di Vizio; A Lucariello; M A Piris
Journal:  J Clin Pathol       Date:  1998-10       Impact factor: 3.411

9.  Transforming properties of the cottontail rabbit papillomavirus oncoproteins Le6 and SE6 and of the E8 protein.

Authors:  J B Harry; F O Wettstein
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

10.  PARP1-Inhibition Sensitizes Cervical Cancer Cell Lines for Chemoradiation and Thermoradiation.

Authors:  Marloes IJff; Gregor G W van Bochove; Denise Whitton; Roy Winiarczyk; Celina Honhoff; Hans Rodermond; Johannes Crezee; Lukas J A Stalpers; Nicolaas A P Franken; Arlene L Oei
Journal:  Cancers (Basel)       Date:  2021-04-26       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.